Market Size of Vietnam Diabetes Care Drugs Industry
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 208.45 Million |
| Market Size (2029) | USD 249.97 Million |
| CAGR (2024 - 2029) | 3.70 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Vietnam Diabetes Care Drugs Market Analysis
The Vietnam Diabetes Care Drugs Market size is estimated at USD 208.45 million in 2024, and is expected to reach USD 249.97 million by 2029, growing at a CAGR of 3.70% during the forecast period (2024-2029).
Vietnam has effectively stopped transmission of the COVID-19 outbreak since the outset, with no deaths for months. Since then, however, the fourth wave of the COVID-19 outbreak has wreaked devastation on Vietnam. According to the Ministry of Health, Vietnam has seen four waves of the COVID-19 epidemic (MOH).
COVID-19 (coronavirus disease) has been found as a highly infectious viral infection caused by coronavirus-2 that produces severe acute respiratory syndrome (SARS-CoV-2). Diabetes is a major risk factor for fatal COVID-19 outcomes. Diabetes patients are vulnerable to infection due to hyperglycemia, impaired immune function, vascular issues, and comorbidities such as hypertension, dyslipidemia, and cardiovascular disease. Furthermore, angiotensin-converting enzyme 2 (ACE2) is a SARS-CoV-2 receptor in humans. As a result, angiotensin-converting enzyme (ACE) inhibitors must be used with caution in diabetic individuals. COVID-19 severity and mortality were significantly higher in diabetics than in non-diabetics. As a result, diabetics should exercise caution during the COVID-19 epidemic.
COVID-19 (coronavirus disease) has been found as a highly infectious viral infection caused by coronavirus-2 that produces severe acute respiratory syndrome (SARS-CoV-2). Diabetes is a major risk factor for fatal COVID-19 outcomes. Diabetes patients are vulnerable to infection due to hyperglycemia, impaired immune function, vascular issues, and comorbidities such as hypertension, dyslipidemia, and cardiovascular disease. Furthermore, angiotensin-converting enzyme 2 (ACE2) is a SARS-CoV-2 receptor in humans. As a result, angiotensin-converting enzyme (ACE) inhibitors must be used with caution in diabetic individuals. COVID-19 severity and mortality were significantly higher in diabetics than in non-diabetics. As a result, diabetics should exercise caution during the COVID-19 epidemic.
In terms of medicines, the insulin category commands a sizable market share. Over 100 million people worldwide use insulin, including all persons with Type 1 diabetes and 10% to 25% of people with Type 2 diabetes. Insulin production is extremely sophisticated, and there are only a few insulin manufacturers on the market. As a result, there is fierce rivalry among these producers, who are continually striving to satisfy the demands of patients by providing the highest-quality insulin.
